View ValuationPyridam Farma 将来の成長Future 基準チェック /06現在、 Pyridam Farmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-Rp533b free cash flow). Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).お知らせ • May 06PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026.Reported Earnings • Apr 04Full year 2025 earnings released: Rp33.79 loss per share (vs Rp38.91 loss in FY 2024)Full year 2025 results: Rp33.79 loss per share. Revenue: Rp2.76t (up 44% from FY 2024). Net loss: Rp379.7b (loss widened 15% from FY 2024).Reported Earnings • Nov 04Third quarter 2025 earnings released: Rp12.21 loss per share (vs Rp10.71 loss in 3Q 2024)Third quarter 2025 results: Rp12.21 loss per share (further deteriorated from Rp10.71 loss in 3Q 2024). Revenue: Rp674.8b (down 11% from 3Q 2024). Net loss: Rp152.6b (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.Board Change • Oct 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 12PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025.Reported Earnings • Nov 03Third quarter 2024 earnings released: Rp10.72 loss per share (vs Rp16.47 loss in 3Q 2023)Third quarter 2024 results: Rp10.72 loss per share. Revenue: Rp754.5b (up 265% from 3Q 2023). Net loss: Rp120.4b (loss widened Rp111.6b from 3Q 2023).New Risk • Oct 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).お知らせ • May 21PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024.New Risk • May 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 20x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risk Market cap is less than US$100m (Rp1.18t market cap, or US$74.3m).New Risk • Apr 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: Rp87.8b (US$5.44m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (27% average weekly change). Market cap is less than US$10m (Rp87.8b market cap, or US$5.44m).Reported Earnings • Mar 16Full year 2023 earnings released: Rp159 loss per share (vs Rp515 profit in FY 2022)Full year 2023 results: Rp159 loss per share (down from Rp515 profit in FY 2022). Revenue: Rp702.1b (down 1.9% from FY 2022). Net loss: Rp85.2b (down 131% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Jan 11PT Pyridam Farma Tbk has filed a Follow-on Equity Offering.PT Pyridam Farma Tbk has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 16,000,000,000 Transaction Features: Rights OfferingNew Risk • Nov 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (Rp524.4b market cap, or US$33.9m).Reported Earnings • Aug 06Second quarter 2023 earnings released: Rp45.55 loss per share (vs Rp12.25 profit in 2Q 2022)Second quarter 2023 results: Rp45.55 loss per share (down from Rp12.25 profit in 2Q 2022). Revenue: Rp148.8b (up 11% from 2Q 2022). Net loss: Rp24.4b (down 472% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.4% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (Rp457.5b market cap, or US$30.5m).Reported Earnings • May 08First quarter 2023 earnings released: Rp23.01 loss per share (vs Rp4.67 profit in 1Q 2022)First quarter 2023 results: Rp23.01 loss per share (down from Rp4.67 profit in 1Q 2022). Revenue: Rp164.9b (down 4.4% from 1Q 2022). Net loss: Rp12.3b (down Rp14.8b from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 08Full year 2022 earnings releasedFull year 2022 results: Revenue: Rp715.4b (up 14% from FY 2021). Net income: Rp275.5b (up Rp270.0b from FY 2021). Profit margin: 39% (up from 0.9% in FY 2021). The increase in margin was primarily driven by lower expenses.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Sep 05Second quarter 2022 earnings released: EPS: Rp12.25 (vs Rp0.96 in 2Q 2021)Second quarter 2022 results: EPS: Rp12.25 (up from Rp0.96 in 2Q 2021). Revenue: Rp134.7b (up 28% from 2Q 2021). Net income: Rp6.56b (up Rp6.04b from 2Q 2021). Profit margin: 4.9% (up from 0.5% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 79% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Aug 28PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiati.PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation August 23, 2021.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to Rp1,240, the stock trades at a trailing P/E ratio of 30x. Average forward P/E is 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 611% over the past three years.Reported Earnings • Jul 04Full year 2020 earnings released: EPS Rp41.31 (vs Rp17.46 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: Rp277.4b (up 12% from FY 2019). Net income: Rp22.1b (up 137% from FY 2019). Profit margin: 8.0% (up from 3.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 24% share price gain to Rp1,200, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 538% over the past three years.Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,235, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 531% over the past three years.Valuation Update With 7 Day Price Move • Jan 18Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to Rp1,120, the stock is trading at a trailing P/E ratio of 29.2x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 472%.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,340, the stock is trading at a trailing P/E ratio of 34.9x, up from the previous P/E ratio of 29.8x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 605%.Is New 90 Day High Low • Jan 11New 90-day high: Rp1,340The company is up 38% from its price of Rp970 on 14 October 2020. The Indonesian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,145, the stock is trading at a trailing P/E ratio of 29.8x, up from the previous P/E ratio of 25.4x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 479%.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to Rp1,035, the stock is trading at a trailing P/E ratio of 27x, down from the previous P/E ratio of 31.8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 481%.Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 30% share price gain to Rp1,150, the stock is trading at a trailing P/E ratio of 30x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 20x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 518%.Is New 90 Day High Low • Dec 08New 90-day high: Rp1,150The company is up 44% from its price of Rp800 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS Rp19.49The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: Rp73.7b (up 16% from 3Q 2019). Net income: Rp10.4b (up 230% from 3Q 2019). Profit margin: 14% (up from 5.0% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 23% share price gain to Rp970, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 31.8x. This compares to an average P/E of 15x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 413%.お知らせ • Aug 04PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion.PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion on July 10, 2020. PT Pyridam Internasional acquired 160.3 million shares at an offer per share IDR 770.91. Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih sold 36.81 million shares, 61.74 million shares and 61.74 million shares respectively. PT Pyridam Internasional Corporation completed the acquisition of additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih on July 10, 2020. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pyridam Farma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測IDX:PYFA - アナリストの将来予測と過去の財務データ ( )IDR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252,760,422-379,670-532,620-364,285N/A9/30/20252,819,223-481,826-709,357-490,843N/A6/30/20252,898,895-451,826-720,773-547,572N/A3/31/20252,454,633-377,733-387,270-211,108N/A12/31/20241,920,812-330,247-262,388-143,816N/A9/30/20241,343,423-246,246-70,426-34,570N/A6/30/2024795,774-140,15875,63496,462N/A3/31/2024688,841-116,016-133,919-114,257N/A12/31/2023702,068-85,221-127,643-103,983N/A9/30/2023684,977-66,72868,56598,887N/A6/30/2023721,928229,50428,31862,609N/A3/31/2023707,846260,664-9,31137,225N/A12/31/2022715,425275,241-40,9855,416N/A9/30/2022775,078278,272-327,843-90,351N/A6/30/2022715,1323,165-294,043-53,566N/A3/31/2022685,557-2,877-238,196-10,694N/A12/31/2021630,5305,479-182,44639,586N/A9/30/2021488,49621,948-39,142-12,029N/A6/30/2021378,33527,773-25,627-14,073N/A3/31/2021315,77728,590-6,3912,217N/A12/31/2020277,39822,104-6,7251,112N/A9/30/2020257,67420,5393,3097,028N/A6/30/2020247,32113,27515,78719,393N/A3/31/2020262,33111,82314,92918,443N/A12/31/2019247,1159,34314,18117,452N/A9/30/2019249,6449,070N/A14,566N/A6/30/2019248,9138,505N/A11,821N/A3/31/2019249,4058,697N/A6,029N/A12/31/2018250,4468,447N/A4,829N/A9/30/2018240,1276,303N/A3,759N/A6/30/2018239,2677,604N/A13,963N/A3/31/2018235,9447,453N/A21,270N/A12/31/2017223,0027,127N/A20,931N/A9/30/2017225,2937,431N/A15,865N/A6/30/2017210,1353,729N/A9,761N/A3/31/2017215,8735,508N/A5,816N/A12/31/2016216,9525,146N/A7,053N/A9/30/2016217,3935,210N/A11,077N/A6/30/2016221,9164,383N/A7,129N/A3/31/2016215,0162,909N/A9,935N/A12/31/2015217,8443,087N/A15,700N/A9/30/2015220,0712,953N/A10,308N/A6/30/2015224,6023,495N/A10,384N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PYFAの予測収益成長が 貯蓄率 ( 6.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PYFAの収益がID市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PYFAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PYFAの収益がID市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PYFAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PYFAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 21:31終値2026/05/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PT Pyridam Farma Tbk 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Elvira NataliaPT Sinarmas Sekuritas
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-Rp533b free cash flow). Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • May 06PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026.
Reported Earnings • Apr 04Full year 2025 earnings released: Rp33.79 loss per share (vs Rp38.91 loss in FY 2024)Full year 2025 results: Rp33.79 loss per share. Revenue: Rp2.76t (up 44% from FY 2024). Net loss: Rp379.7b (loss widened 15% from FY 2024).
Reported Earnings • Nov 04Third quarter 2025 earnings released: Rp12.21 loss per share (vs Rp10.71 loss in 3Q 2024)Third quarter 2025 results: Rp12.21 loss per share (further deteriorated from Rp10.71 loss in 3Q 2024). Revenue: Rp674.8b (down 11% from 3Q 2024). Net loss: Rp152.6b (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.
Board Change • Oct 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 12PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025.
Reported Earnings • Nov 03Third quarter 2024 earnings released: Rp10.72 loss per share (vs Rp16.47 loss in 3Q 2023)Third quarter 2024 results: Rp10.72 loss per share. Revenue: Rp754.5b (up 265% from 3Q 2023). Net loss: Rp120.4b (loss widened Rp111.6b from 3Q 2023).
New Risk • Oct 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).
お知らせ • May 21PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024.
New Risk • May 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 20x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risk Market cap is less than US$100m (Rp1.18t market cap, or US$74.3m).
New Risk • Apr 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: Rp87.8b (US$5.44m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (27% average weekly change). Market cap is less than US$10m (Rp87.8b market cap, or US$5.44m).
Reported Earnings • Mar 16Full year 2023 earnings released: Rp159 loss per share (vs Rp515 profit in FY 2022)Full year 2023 results: Rp159 loss per share (down from Rp515 profit in FY 2022). Revenue: Rp702.1b (down 1.9% from FY 2022). Net loss: Rp85.2b (down 131% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Jan 11PT Pyridam Farma Tbk has filed a Follow-on Equity Offering.PT Pyridam Farma Tbk has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 16,000,000,000 Transaction Features: Rights Offering
New Risk • Nov 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (Rp524.4b market cap, or US$33.9m).
Reported Earnings • Aug 06Second quarter 2023 earnings released: Rp45.55 loss per share (vs Rp12.25 profit in 2Q 2022)Second quarter 2023 results: Rp45.55 loss per share (down from Rp12.25 profit in 2Q 2022). Revenue: Rp148.8b (up 11% from 2Q 2022). Net loss: Rp24.4b (down 472% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.4% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (Rp457.5b market cap, or US$30.5m).
Reported Earnings • May 08First quarter 2023 earnings released: Rp23.01 loss per share (vs Rp4.67 profit in 1Q 2022)First quarter 2023 results: Rp23.01 loss per share (down from Rp4.67 profit in 1Q 2022). Revenue: Rp164.9b (down 4.4% from 1Q 2022). Net loss: Rp12.3b (down Rp14.8b from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 08Full year 2022 earnings releasedFull year 2022 results: Revenue: Rp715.4b (up 14% from FY 2021). Net income: Rp275.5b (up Rp270.0b from FY 2021). Profit margin: 39% (up from 0.9% in FY 2021). The increase in margin was primarily driven by lower expenses.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Sep 05Second quarter 2022 earnings released: EPS: Rp12.25 (vs Rp0.96 in 2Q 2021)Second quarter 2022 results: EPS: Rp12.25 (up from Rp0.96 in 2Q 2021). Revenue: Rp134.7b (up 28% from 2Q 2021). Net income: Rp6.56b (up Rp6.04b from 2Q 2021). Profit margin: 4.9% (up from 0.5% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 79% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Aug 28PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiati.PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation August 23, 2021.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to Rp1,240, the stock trades at a trailing P/E ratio of 30x. Average forward P/E is 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 611% over the past three years.
Reported Earnings • Jul 04Full year 2020 earnings released: EPS Rp41.31 (vs Rp17.46 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: Rp277.4b (up 12% from FY 2019). Net income: Rp22.1b (up 137% from FY 2019). Profit margin: 8.0% (up from 3.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 24% share price gain to Rp1,200, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 538% over the past three years.
Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,235, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 531% over the past three years.
Valuation Update With 7 Day Price Move • Jan 18Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to Rp1,120, the stock is trading at a trailing P/E ratio of 29.2x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 472%.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,340, the stock is trading at a trailing P/E ratio of 34.9x, up from the previous P/E ratio of 29.8x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 605%.
Is New 90 Day High Low • Jan 11New 90-day high: Rp1,340The company is up 38% from its price of Rp970 on 14 October 2020. The Indonesian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,145, the stock is trading at a trailing P/E ratio of 29.8x, up from the previous P/E ratio of 25.4x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 479%.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to Rp1,035, the stock is trading at a trailing P/E ratio of 27x, down from the previous P/E ratio of 31.8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 481%.
Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 30% share price gain to Rp1,150, the stock is trading at a trailing P/E ratio of 30x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 20x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 518%.
Is New 90 Day High Low • Dec 08New 90-day high: Rp1,150The company is up 44% from its price of Rp800 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS Rp19.49The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: Rp73.7b (up 16% from 3Q 2019). Net income: Rp10.4b (up 230% from 3Q 2019). Profit margin: 14% (up from 5.0% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 23% share price gain to Rp970, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 31.8x. This compares to an average P/E of 15x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 413%.
お知らせ • Aug 04PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion.PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion on July 10, 2020. PT Pyridam Internasional acquired 160.3 million shares at an offer per share IDR 770.91. Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih sold 36.81 million shares, 61.74 million shares and 61.74 million shares respectively. PT Pyridam Internasional Corporation completed the acquisition of additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih on July 10, 2020.